ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 1673 • ACR Convergence 2020

    Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort

    Kathleen Vazzana1, Ankana Daga2, Beatrice Goilav3, Ekemini Ogbu4, Daryl Okamura5, Catherine Park6, Rebecca Sadun7, Emily Smitherman8, Brian Stotter9, Scott Wenderfer10 and Laura Lewandowski11, 1National Institute of Health/Children's National Hospital, Washington, DC, 2Harvard, Boston, MA, 3The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 4Johns Hopkins University, Baltimore, MD, 5Seattle's Children's, Seattle, WA, 6Emory University, Atlanta, GA, 7Duke University, Durham, NC, 8University of Alabama at Birmingham, Birmingham, AL, 9Washington University School of Medicine, St. Louis, MO, 10Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 11NIAMS, NIH, Rockville, MD

    Background/Purpose: Lupus nephritis (LN) is a well-established and life-threatening manifestation of systemic lupus erythematosus (SLE) that is more common in children than adults. The demographics…
  • Abstract Number: 1833 • ACR Convergence 2020

    Hydroxychloroquine and Vitamin D Both Reduce Proteinuria in SLE

    Michelle Petri1, Jessica Li2 and Daniel Goldman1, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Johns Hopkins University, Baltimore, MD

    Background/Purpose: Hydroxychloroquine (HCQ) and vitamin D are both immunomodulators in SLE, but work through different mechanisms.  Hydroxychloroquine has been proven to triple renal response to…
  • Abstract Number: 0274 • ACR Convergence 2020

    The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades

    Mehmet Hocaoglu1, Shirley-Ann Osei-Onomah2, Jesse Dabit3, Rachel Giblon3, Thomas O'Byrne3, Fernando C. Fervenza3, Cynthia Crowson4 and Ali Duarte-Garcia3, 1University of Maryland Medical Center Midtown Campus, Baltimore, MD, 2Mayo Clinic, Rochester, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Estimating the incidence of lupus nephritis (LN) is important to understand disease burden, particularly since patients with LN have a higher morbidity and mortality…
  • Abstract Number: 0976 • ACR Convergence 2020

    Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion

    Shuchi Smita1, Minjung Kim1, Maria Chikina1, Mark Shlomchik1 and Jeremy Tilstra1, 1University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Lupus nephritis (LN) is a hallmark of SLE, affecting 50-60% of patients within 10 years of diagnosis. Current treatments for LN have suboptimal response…
  • Abstract Number: 1674 • ACR Convergence 2020

    Pediatric and Adolescent One Year Protocol Kidney Biopsies Should Be Performed, Even in Patients with Complete Remission of Their Lupus Nephritis

    Peter Yorgin1, Suhas Radhakrishna1, Caitlin Carter1, Johanna Chang1, Katayoon Shayan1, Lieuko Nguyen1, Peter Chiraseveenuprapund1 and Robert Sheets2, 1UCSD/Rady Children's Hospital, San Diego, CA, 2University of California San Diego, San Diego, CA

    Background/Purpose: The value of one-year protocol kidney biopsies in children who have proliferative lupus nephritis (LN) is unclear, particularly in patients who meet CARRA criteria…
  • Abstract Number: 1836 • ACR Convergence 2020

    Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis

    Zahir Amoura1, Philippe Remy2, Luis Fernando Quintana Porras3, Laurent Chiche4, Dominique Chauveau5, Dario Roccatello6, Richard Furie7, Thomas Schindler8, Jay Garg9, Matthew Cascino9, Brad Rovin10 and Andrea Doria11, 1Hôpital Pitié-Salpêtrière, Paris, 2APHP Groupe Hospitalier Henri-Mondor, Creteil, France, 3Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 4Hôpital Européen, Marseille, France, 5Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, 6S Giovanni Hospital, Univ of Turin, Turin, Italy, 7Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 8F. Hoffmann-La Roche Ltd., Basel, Switzerland, 9Genentech, Inc., South San Francisco, CA, 10The Ohio State University, Columbus, 11University of Padua, Padua, Italy

    Background/Purpose: Obinutuzumab, a type II anti-CD20 mAb, resulted in rapid and complete B-cell depletion and improved renal responses in proliferative lupus nephritis (LN) in the…
  • Abstract Number: 0288 • ACR Convergence 2020

    Targeted Sequencing Revealed Novel Candidate Genetic Contributions to Lupus Nephritis in a Cohort of Swedish Patients with Systemic Lupus Erythematosus

    Sule Yavuz1, Pascal Pucholt2, Dag Leonard2, Juliana Imgenberg-Kreuz2, Matteo Bianchi2, Johanna Sandling2, Iva Gunnarsson3, Swedish Sle Network2 and Lars Ronnblom2, 1Uppsala University Rheumatology, Doral, FL, 2Uppsala University, Uppsala, Sweden, 3Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Lupus nephritis (LN) is a common debilitating manifestation of Systemic Lupus Erythematosus (SLE). Despite improved understanding of underlying mechanisms driving to LN and early…
  • Abstract Number: 0979 • ACR Convergence 2020

    The Identification of Shared and Unique Myeloid Cell States in Pre- and Post-nephritic Lupus Mouse Models, Sle.Yaa1 and NZBW

    Paul Hoover1, Michael Peters2, David Lieb3, Heather Geiger4, Rakesh Mishra5, Nir Hacohen2 and Anne Davidson6, 1Brigham and Women's Hospital, Boston, MA, 2Broad Institute, Boston, 3Broad Institute, Boston, MA, 4New York Genome Center, New York, NY, 5Feinstein Institute, Manhasset, NY, 6Northwell Health, New York

    Background/Purpose:Poor renal prognosis in lupus nephritis (LN) is associated with an abundance of renal macrophages and dendritic cells (DCs) but the role of these cells…
  • Abstract Number: 1678 • ACR Convergence 2020

    Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis

    Verena Balbi1, Clovis Silva2, Tatiana Pedrosa3, Rosa Pereira3, Lucia Campos3, Elaine Leon3, Nilo Duarte3, Valdemir Carvalho4, Sandra Pasoto3, Debora Rosario3, Leticia Brandao3, Eloisa Bonfa3 and Nadia Aikawa3, 1Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao paulo, Brazil, 2Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, 3Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, 4Fleury Group, Sao Paulo, Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Renal involvement is reported in up to 80% of juvenile systemic lupus erithematosus (JSLE) and its among the most severe manifestations in these population. Antimalarials are one of…
  • Abstract Number: 1843 • ACR Convergence 2020

    Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids

    Ellen M Ginzler1, Joshua Kaplan2, Laura Lisk3, Ray Federico4, Neil Solomons5 and Robert Huizinga5, 1SUNY Downstate Health Sciences University, Brooklyn, 2Rutgers University, New Brunswick, NJ, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, 4Aurinia Pharmaceuticals, Inc., Victoria, Canada, 5Aurinia Pharmaceuticals, Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for…
  • Abstract Number: 0289 • ACR Convergence 2020

    Endogenous Interferon-β and Low IL-4R on Transitional B Cells Promotes Lupus Nephritis

    Fatima Alduraibi1, Huma Fatima1, W. Winn Chatham1, Hui-Chen Hsu1 and John Mountz2, 1University of Alabama at Birmingham, Birmingham, AL, 2University Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: We previously showed that B-cell endogenous interferon-beta (IFNβ) at the transitional (Tr) stage correlates with development of anti-Smith (anti-Sm) and renal disease as well…
  • Abstract Number: 0980 • ACR Convergence 2020

    Hospitalized Infections in Lupus: A Nationwide Study of Types of Infections, Time-trends, Healthcare Utilization and In-Hospital Mortality

    Jasvinder Singh1 and John Cleveland1, 1University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: To examine the time-trends in hospitalized infections in lupus and the factors associated with healthcare utilization and in-hospital mortality.Methods: We used the U.S. National…
  • Abstract Number: 1679 • ACR Convergence 2020

    Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis

    Nathalie Chalhoub1, Kelly Rouster-Stevens2, Marisa Klein-Gitelman3, Karen Onel4, Beatrice Goilav5, Sonia Savani6, Natasha Ruth6, Tingting Qiu7, Najla Aljaberi8, Jianghong Deng9, Angela Merritt8, Benjamin Laskin10, Anna Carmela Sagcal-Gironella11, Stacy Ardoin12, Deborah Levy13, Scott Wenderfer14, Bin Huang7, Hermine I Brunner15 and LaUNCH Project Investigators16, 1The University of Cincinnati College of Medicine, Cincinnati, OH, 2Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 3Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 4Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, 5The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 6Medical University of South Carolina, Charleston, SC, 7Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Beijing Children’s Hospital, Beijing, China (People's Republic), 10Children's Hospital of Philadelphia, Philadelphia, 11Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ, 12Nationwide Children's Hospital, Columbus, OH, 13Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 14Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 15PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 16LUpus Nephritis and Cellcept precision dosing in cHildren (LaUNCH), Cincinnati, OH

    Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…
  • Abstract Number: 0598 • ACR Convergence 2020

    Impact of a Dedicated Lupus Nephritis Clinic to Improve Time to Biopsy and Care Quality

    Shivani Garg1, Callie Plafkin2, Tripti Singh1, Sarah Panzer3 and Christie Bartels4, 1UW Madison, Madison, WI, 2UW Madison, Madison, 3UW-Madison, Madison, 4University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

    Background/Purpose: Lupus nephritis (LN) contributes to a 10-fold higher risk to develop kidney failure and 26-fold higher mortality compared to peers. Kidney biopsy remains a…
  • Abstract Number: 0988 • ACR Convergence 2020

    Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis

    Richard Furie1, Gustavo Aroca2, Analia Alvarez3, Hilda Fragoso-Loyo4, Elizabeth Zuta Santillan5, Brad Rovin6, Paul Brunetta7, Thomas Schindler8, Imran Hassan9, Matthew Cascino10, Jay Garg10 and Ana Malvar11, 1Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 2Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia, 3CEMIC, Buenos Aires, Argentina, 4Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 5Instituto de Ginecología y Reproducción, Lima, Peru, 6The Ohio State University, Columbus, 7Genentech, Inc., South San Francisco, 8F. Hoffmann-La Roche Ltd., Basel, Switzerland, 9Hoffmann-La Roche Ltd, Mississauga, Canada, 10Genentech, Inc., South San Francisco, CA, 11Organizacion Medica de Investigacion, Buenos Aires, Argentina

    Background/Purpose: NOBILITY demonstrated improved renal responses and complete B-cell depletion with the humanized type II anti-CD20 monoclonal antibody obinutuzumab (OBI) compared with placebo (PBO) through…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology